DDInter1476 DDInter1110
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Terbutaline {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aripiprazole
Aripiprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atropine
Atropine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Pirbuterol {u} (Compound) resembles {v} (Compound) Nadolol
Nadolol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Macimorelin
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may lead to a major life threatening interaction when taken with Macimorelin
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Salbutamol (Compound) and Salbutamol may lead to a major life threatening interaction when taken with Macimorelin
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Pirbuterol (Compound) resembles Terbutaline (Compound) and Terbutaline (Compound) resembles Salbutamol (Compound) and Salbutamol may lead to a major life threatening interaction when taken with Macimorelin
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Macimorelin
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Pirbuterol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Pirbuterol (Compound) resembles Nadolol (Compound) and Nadolol may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin